Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Major Depressive Disorder (MDD), Pharmacogenomics, Antidepressant Therapy, Personalized Medicine, CYP2D6, CYP2C19

View Full Paper
Ask AI
Bookmark
Share

Authors

RMR Meena

Discussion

Loading...

Member takes

Overview

This observational study examines the role of pharmacogenomics in antidepressant therapy for MDD, indicating better outcomes through personalization.

Key Points

  • Pharmacogenomic-guided therapy significantly improves treatment effectiveness for patients with major depressive disorder.
  • In the cohort of 150 MDD patients, a strong association was found between genotype patterns and clinical outcomes.
  • The study focused on genotypic differences in CYP2D6 and CYP2C19 to inform antidepressant selection.
  • Introducing pharmacogenomic screening in psychiatric care could enhance patient quality of life and reduce adverse effects.

Cite This Study

R Meena (2025) studied this question.

synapsesocial.com/papers/68c1b1a154b1d3bfb60e9230https://doi.org/10.64062/jpgmb.vol1.issue4.14
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacogenetic testing for selection of antidepressant treatment2024
  2. 2Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019–20242025 · 6 citations
  3. 3Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder2025
  4. 4Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use2026
  5. 5Personalizing Antidepressant Therapy: Integrating Pharmacogenomics, Therapeutic Drug Monitoring, and Digital Tools for Improved Depression Outcomes2025 · 5 citations